$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000143774923013767 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$21.14M	$17.19M
YoY Change	27.31%	26.75%
Cost Of Revenue	$2.443M	$2.265M
YoY Change	32.34%	48.52%
Gross Profit	$18.70M	$14.93M
YoY Change	26.68%	23.99%
Gross Profit Margin	88.44%	86.83%
Selling, General & Admin	$22.49M	$24.47M
YoY Change	7.97%	14.9%
% of Gross Profit	120.31%	163.96%
Research & Development	$11.58M	$12.50M
YoY Change	-8.35%	-1.56%
% of Gross Profit	61.96%	83.73%
Depreciation & Amortization	$200.0K	$200.0K
YoY Change	0.0%	0.0%
% of Gross Profit	1.07%	1.34%
Operating Expenses	$34.08M	$36.97M
YoY Change	1.81%	8.75%
Operating Profit	-$15.38M	-$22.05M
YoY Change	-17.81%	0.4%
Interest Expense	-$3.326M	-$2.908M
YoY Change	50.29%	938.57%
% of Operating Profit
Other Income/Expense, Net	-$5.374M	-$15.00K
YoY Change	-6.23%	-99.74%
Pretax Income	-$24.08M	-$30.19M
YoY Change	-9.67%	7.57%
Income Tax	$54.00K	$21.00K
% Of Pretax Income
Net Earnings	-$24.14M	-$30.21M
YoY Change	-9.57%	6.41%
Net Earnings / Revenue	-114.18%	-175.74%
Basic Earnings Per Share	-$1.03	-$1.30
Diluted Earnings Per Share	-$1.03	-$1.30
COMMON SHARES
Basic Shares Outstanding	23.45M	23.44M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$47.30M	$65.05M
YoY Change	-57.67%	-52.32%
Cash & Equivalents	$20.13M	$36.54M
Short-Term Investments	$27.17M	$28.51M
Other Short-Term Assets	$13.54M	$12.96M
YoY Change	20.41%	31.91%
Inventory	$4.988M	$5.466M
Prepaid Expenses
Receivables	$15.51M	$12.49M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$81.33M	$95.97M
YoY Change	-41.75%	-40.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$910.0K	$1.103M
YoY Change	-43.3%	-37.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$7.970M	$10.17M
YoY Change	1084.25%	1408.16%
Other Assets	$2.817M	$3.160M
YoY Change	48.26%	101.02%
Total Long-Term Assets	$14.03M	$16.98M
YoY Change	115.25%	227.12%
TOTAL ASSETS
Total Short-Term Assets	$81.33M	$95.97M
Total Long-Term Assets	$14.03M	$16.98M
Total Assets	$95.36M	$113.0M
YoY Change	-34.75%	-31.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.659M	$6.968M
YoY Change	89.62%	64.57%
Accrued Expenses	$19.38M	$16.05M
YoY Change	44.21%	36.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.77M	$25.23M
YoY Change	48.36%	32.18%
LONG-TERM LIABILITIES
Long-Term Debt	$98.30M	$97.94M
YoY Change	38.06%	38.34%
Other Long-Term Liabilities	$108.7M	$106.3M
YoY Change	11.16%	14.46%
Total Long-Term Liabilities	$98.30M	$97.94M
YoY Change	38.06%	38.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.77M	$25.23M
Total Long-Term Liabilities	$98.30M	$97.94M
Total Liabilities	$233.8M	$229.5M
YoY Change	24.99%	25.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$631.5M	-$607.3M
YoY Change	20.88%	22.51%
Common Stock	$493.2M	$490.8M
YoY Change	2.41%	2.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$138.4M	-$116.6M
YoY Change
Total Liabilities & Shareholders Equity	$95.36M	$113.0M
YoY Change	-34.75%	-31.84%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$24.14M	-$30.21M
YoY Change	-9.57%	6.41%
Depreciation, Depletion And Amortization	$200.0K	$200.0K
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$20.27M	-$25.81M
YoY Change	-16.22%	7.55%
INVESTING ACTIVITIES
Capital Expenditures	$15.00K	$23.00K
YoY Change	-123.81%	-8.0%
Acquisitions
YoY Change
Other Investing Activities	$3.735M	$6.293M
YoY Change	-4344.32%	-53.8%
Cash From Investing Activities	$3.720M	$6.270M
YoY Change	-2563.58%	-53.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	143.0K	$671.0K
YoY Change	-285.71%	-99.05%
NET CHANGE
Cash From Operating Activities	-20.27M	-$25.81M
Cash From Investing Activities	3.720M	$6.270M
Cash From Financing Activities	143.0K	$671.0K
Net Change In Cash	-16.41M	-$18.87M
YoY Change	-32.82%	-131.27%
FREE CASH FLOW
Cash From Operating Activities	-$20.27M	-$25.81M
Capital Expenditures	$15.00K	$23.00K
Free Cash Flow	-$20.29M	-$25.83M
YoY Change	-15.94%	7.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23440521
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23440521
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23129953
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23129953
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-89361000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	62000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30213000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38079
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1460746
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Alexander Park Drive
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
CY2023Q1	dei	City Area Code CityAreaCode	646
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	768-9780
CY2023Q1	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.01 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	URGN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1103000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	usd
CY2023Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	224000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2329000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2452000	usd
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	10165000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3160000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2740000	usd
CY2023Q1	us-gaap	Assets Assets	112954000	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23453672
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36540000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55408000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	28514000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44556000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	814000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	813000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12493000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12704000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	5466000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4325000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12146000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11101000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	95973000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	128907000	usd
CY2022Q4	us-gaap	Assets Assets	135619000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17130000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12383000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4919000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8257000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3185000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3276000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	25234000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23916000	usd
CY2023Q1	urgn	Prepaid Forward Obligation PrepaidForwardObligation	101912000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97941000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97537000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1403000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1586000	usd
CY2023Q1	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	3018000	usd
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	3018000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	229508000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	224980000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	64000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	63000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	490744000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	487787000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-607317000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577104000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-45000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-107000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-116554000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-89361000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112954000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	135619000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17192000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13564000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	2265000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	1525000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	14927000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	12039000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12498000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12696000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24474000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21300000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22045000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-21957000	usd
CY2023Q1	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5224000	usd
CY2022Q1	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5826000	usd
CY2023Q1	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	3553000	usd
CY2022Q1	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	282000	usd
CY2023Q1	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	630000	usd
CY2022Q1	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	-2000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30192000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28067000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23996000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	325000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30213000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28392000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30213000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28392000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	62000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-44000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30151000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28436000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23279951
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22631509
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	672000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2286000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-116554000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2949000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-44000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28392000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-17074000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30213000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28392000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	217000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	215000	usd
CY2023Q1	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	2873000	usd
CY2022Q1	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	4289000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	354000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-50000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2286000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2949000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	404000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	282000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	218000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	241000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1140000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-76000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-211000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2218000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1045000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1800000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	421000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	169000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4747000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2169000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3338000	usd
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1801000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	301000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-252000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-286000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25807000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	24176000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	-0	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	30469000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1188000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	491000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	13621000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6270000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13596000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	671000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	70831000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	89000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	671000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70742000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18866000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	60342000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56220000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45587000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37354000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	105929000	usd
CY2023Q1	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	95000	usd
CY2022Q1	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	6000	usd
CY2023Q1	urgn	Issuance Costs Incurred During Noncash Or Partial Noncash Transaction IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2022Q1	urgn	Issuance Costs Incurred During Noncash Or Partial Noncash Transaction IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	3000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Business and Nature of Operations</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma, Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> clinical development of UGN-<em style="font: inherit;">102,</em> and raising capital to support and expand these activities.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low-grade UTUC”). <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <i>RTGel</i> technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p>
CY2023Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>–<b> Basis of Presentation</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> as filed with the U.S. Securities and Exchange Commission (“SEC”) on <em style="font: inherit;"> March 24, 2023.</em></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color:#ffffff;">f $607.3 </span>million and $577.1 million as of <em style="font: inherit;"> March 31, 2023</em> and <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for the next <em style="font: inherit;">12</em> months from the date the financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments relating to the carrying amounts and classification of assets and liabilities that <em style="font: inherit;"> may </em>be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from <i>Jelmyto</i> product sales and develop UGN-<em style="font: inherit;">102.</em> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company believes that absent sufficient proceeds received from equity, financing, or business development transactions, the Company will <em style="font: inherit;">not</em> have sufficient cash and cash equivalents to fund its operations beyond <em style="font: inherit;">one</em> year from the issuance of these financial statements. Accordingly, the Company will, over the next <em style="font: inherit;">12</em> months, require significant additional financing to continue its operations. In addition, there can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing if at all, on terms that are satisfactory to the Company, and in amounts sufficient to meet its needs. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Failure to successfully receive additional financing will require the Company to delay, limit or reduce product development and commercialization efforts.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-607300000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577100000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17130000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12383000	usd
CY2022Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	2853000	usd
CY2023Q1	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	822000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"/>
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	75200000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"/>
CY2022Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1285000	usd
CY2023Q1	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	4185000	usd
CY2022Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	1609000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6968000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5527000	usd
CY2023Q1	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	1646000	usd
CY2022Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	618000	usd
CY2023Q1	urgn	Accrued Clinical Expense AccruedClinicalExpense	2321000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	38679000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	645000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4000	usd
CY2023Q1	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	630000	usd
CY2022Q1	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	-2000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5297000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4676000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2960000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2019000	usd
CY2023Q1	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	8257000	usd
CY2022Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	6695000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	38724000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	36000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	81000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	39382000	usd
CY2023Q1	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax	36000	usd
CY2023Q1	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Losses Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax	81000	usd
CY2023Q1	urgn	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	39337000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	22200000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	29172000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	44556000	usd
CY2023Q1	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	10165000	usd
CY2022Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	0	usd
CY2023Q1	us-gaap	Investments Investments	39337000	usd
CY2022Q4	us-gaap	Investments Investments	44556000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4470000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4447000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3367000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3150000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1103000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	usd
CY2021	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21559000	usd
CY2021	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	8349000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2023Q1	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5224000	usd
CY2023Q1	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	2235000	usd
CY2023Q1	urgn	Prepaid Forward Obligation PrepaidForwardObligation	101912000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	228000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	259000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	56000	usd
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	56000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	19000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	17000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	191000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	220000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2329000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2452000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1403000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1586000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	294000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	296000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	95000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M4D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M10D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1012	pure
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0578	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	877000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	930000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	816000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	53000	usd
CY2023Q1	urgn	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2676000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	305000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2371000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	188000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	49000	usd
CY2023Q1	urgn	Lessor Operating Lease Payment To Be Received After Next Year LessorOperatingLeasePaymentToBeReceivedAfterNextYear	0	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	237000	usd
CY2022Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	1437000	usd
CY2023Q1	urgn	Sales Reserve Accruals SalesReserveAccruals	5236000	usd
CY2023Q1	urgn	Sales Reserve Utilization SalesReserveUtilization	-4530000	usd
CY2023Q1	urgn	Accrued Sales Reserve AccruedSalesReserve	2143000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23400000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23100000
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3545519
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1020735
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2286000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2949000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	14.2	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3000000.0	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	1100000	usd

Files In Submission

Name	View Source	Status
0001437749-23-013767-index-headers.html	Edgar Link	pending
0001437749-23-013767-index.html	Edgar Link	pending
0001437749-23-013767.txt	Edgar Link	pending
0001437749-23-013767-xbrl.zip	Edgar Link	pending
ex_470745.htm	Edgar Link	pending
ex_470746.htm	Edgar Link	pending
ex_470747.htm	Edgar Link	pending
ex_470748.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-20230331.xsd	Edgar Link	pending
urgn20230331_10q.htm	Edgar Link	pending
urgn-20230331_cal.xml	Edgar Link	unprocessable
urgn-20230331_def.xml	Edgar Link	unprocessable
urgn-20230331_pre.xml	Edgar Link	unprocessable
urgn-20230331_lab.xml	Edgar Link	unprocessable
urgn20230331_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2023 Q2 Form 10-Q Financial Statement

#000143774923013767 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2023 Q2 Form 10-Q Financial Statement

#000143774923013767 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn